DAY 6
Liposomal Amphotericin B initiated*
following renal decline
following renal decline
During routine drug monitoring, it was found that
Mustafa's serum creatinine levels were rising,
indicating a decline in his kidney function.
Mustafa's serum creatinine levels were rising,
indicating a decline in his kidney function.
*Please refer to the Summary of Product Characteristics of your chosen treatment prior to prescribing.
**Administration of a test dose is advisable before a new course of Liposomal Amphotericin B treatment.
Therapy is usually started at a daily dose of 1.0 mg/kg and increased stepwise to 3.0 mg/kg, as required.1
†Liposomal Amphotericin B has been shown to be substantially less toxic than conventional amphotericin B,
particularly with respect to nephrotoxicity; however, renal adverse reactions may still occur. If clinically
significant reduction in renal function or worsening of other parameters occurs, consideration should be
given to dose reduction, treatment interruption or discontinuation.1
**Administration of a test dose is advisable before a new course of Liposomal Amphotericin B treatment.
Therapy is usually started at a daily dose of 1.0 mg/kg and increased stepwise to 3.0 mg/kg, as required.1
†Liposomal Amphotericin B has been shown to be substantially less toxic than conventional amphotericin B,
particularly with respect to nephrotoxicity; however, renal adverse reactions may still occur. If clinically
significant reduction in renal function or worsening of other parameters occurs, consideration should be
given to dose reduction, treatment interruption or discontinuation.1
Mustafa's antifungal treatment was changed to
Liposomal Amphotericin B**,† (3 mg/kg/day).
Liposomal Amphotericin B**,† (3 mg/kg/day).
Why Liposomal Amphotericin B
Decision point
